Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study

Background: Sorafenib is the currently recommended therapy in patients with advanced hepatocellular carcinoma (HCC). Among the several biomarkers available for the evaluation of the therapeutic response and prognosis, there is perfusion magnetic resonance imaging (p-MRI) that, through measurement of the vascular permeability unit (ktrans), may retrieve useful information regarding the microvascular properties of focal liver lesions. The aim of this study was to evaluate the impact of sorafenib therapy in patients with advanced HCC using the p-MRI technique. Materials and Methods: In this retrospective study, 27 patients with the diagnosis of advanced HCC were included for palliative therapy using sorafenib. MRI of the liver was performed before the beginning of the oral therapy (T0), after 3 (T3), and after 6 months (T6). Dynamic acquisitions of the tumor (n = 50, during the first 2 min after contrast injection) were obtained in the coronal plane and were used to compute the parametric perfusion maps, acquiring the ktrans value using the extended Tofts pharmacokinetic model. Results: The value of ktrans obtained at T0 was significantly different from the value of ktrans obtained at T6 (p = 0.028). There were no significant differences between T0 and T3 (p = 0.115) or a correlation between ktrans at T0 and the size of the lesion (p = 0.376). The ktrans value at T0 in patients with progressionfree survival (PFS) > 6 months was not significantly different from the ktrans value in patients with PFS ≤6 months (p = 0.113). The ktrans value at T0 was not significantly different between patients who were previously submitted to chemoembolization and those who were not submitted (p = 0.587). Conclusion: In this pilot study, the ktrans value may serve as a biomarker of tumor response to antiangiogenic therapy, but only 6 months after its initiation. Clinical outcomes such as PFS were not predicted before the initiation of treatment.

Saved in:
Bibliographic Details
Main Authors: Campos,Marta, Candelária,Isabel, Papanikolaou,Nickolas, Simão,Adélia, Ferreira,Carlos, Manikis,Georgios C., Caseiro-Alves,Filipe
Format: Digital revista
Language:English
Published: Sociedade Portuguesa de Gastrenterologia 2019
Online Access:http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452019000400006
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2341-45452019000400006
record_format ojs
spelling oai:scielo:S2341-454520190004000062019-11-19Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot StudyCampos,MartaCandelária,IsabelPapanikolaou,NickolasSimão,AdéliaFerreira,CarlosManikis,Georgios C.Caseiro-Alves,Filipe Hepatocellular carcinoma Sorafenib Angiogenesis Magnetic resonance imaging perfusion ktrans Tumor markers Background: Sorafenib is the currently recommended therapy in patients with advanced hepatocellular carcinoma (HCC). Among the several biomarkers available for the evaluation of the therapeutic response and prognosis, there is perfusion magnetic resonance imaging (p-MRI) that, through measurement of the vascular permeability unit (ktrans), may retrieve useful information regarding the microvascular properties of focal liver lesions. The aim of this study was to evaluate the impact of sorafenib therapy in patients with advanced HCC using the p-MRI technique. Materials and Methods: In this retrospective study, 27 patients with the diagnosis of advanced HCC were included for palliative therapy using sorafenib. MRI of the liver was performed before the beginning of the oral therapy (T0), after 3 (T3), and after 6 months (T6). Dynamic acquisitions of the tumor (n = 50, during the first 2 min after contrast injection) were obtained in the coronal plane and were used to compute the parametric perfusion maps, acquiring the ktrans value using the extended Tofts pharmacokinetic model. Results: The value of ktrans obtained at T0 was significantly different from the value of ktrans obtained at T6 (p = 0.028). There were no significant differences between T0 and T3 (p = 0.115) or a correlation between ktrans at T0 and the size of the lesion (p = 0.376). The ktrans value at T0 in patients with progressionfree survival (PFS) > 6 months was not significantly different from the ktrans value in patients with PFS ≤6 months (p = 0.113). The ktrans value at T0 was not significantly different between patients who were previously submitted to chemoembolization and those who were not submitted (p = 0.587). Conclusion: In this pilot study, the ktrans value may serve as a biomarker of tumor response to antiangiogenic therapy, but only 6 months after its initiation. Clinical outcomes such as PFS were not predicted before the initiation of treatment.info:eu-repo/semantics/openAccessSociedade Portuguesa de GastrenterologiaGE-Portuguese Journal of Gastroenterology v.26 n.4 20192019-08-01info:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452019000400006en10.1159/000493351
institution SCIELO
collection OJS
country Portugal
countrycode PT
component Revista
access En linea
databasecode rev-scielo-pt
tag revista
region Europa del Sur
libraryname SciELO
language English
format Digital
author Campos,Marta
Candelária,Isabel
Papanikolaou,Nickolas
Simão,Adélia
Ferreira,Carlos
Manikis,Georgios C.
Caseiro-Alves,Filipe
spellingShingle Campos,Marta
Candelária,Isabel
Papanikolaou,Nickolas
Simão,Adélia
Ferreira,Carlos
Manikis,Georgios C.
Caseiro-Alves,Filipe
Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study
author_facet Campos,Marta
Candelária,Isabel
Papanikolaou,Nickolas
Simão,Adélia
Ferreira,Carlos
Manikis,Georgios C.
Caseiro-Alves,Filipe
author_sort Campos,Marta
title Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study
title_short Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study
title_full Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study
title_fullStr Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study
title_full_unstemmed Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study
title_sort perfusion magnetic resonance as a biomarker for sorafenib-treated advanced hepatocellular carcinoma: a pilot study
description Background: Sorafenib is the currently recommended therapy in patients with advanced hepatocellular carcinoma (HCC). Among the several biomarkers available for the evaluation of the therapeutic response and prognosis, there is perfusion magnetic resonance imaging (p-MRI) that, through measurement of the vascular permeability unit (ktrans), may retrieve useful information regarding the microvascular properties of focal liver lesions. The aim of this study was to evaluate the impact of sorafenib therapy in patients with advanced HCC using the p-MRI technique. Materials and Methods: In this retrospective study, 27 patients with the diagnosis of advanced HCC were included for palliative therapy using sorafenib. MRI of the liver was performed before the beginning of the oral therapy (T0), after 3 (T3), and after 6 months (T6). Dynamic acquisitions of the tumor (n = 50, during the first 2 min after contrast injection) were obtained in the coronal plane and were used to compute the parametric perfusion maps, acquiring the ktrans value using the extended Tofts pharmacokinetic model. Results: The value of ktrans obtained at T0 was significantly different from the value of ktrans obtained at T6 (p = 0.028). There were no significant differences between T0 and T3 (p = 0.115) or a correlation between ktrans at T0 and the size of the lesion (p = 0.376). The ktrans value at T0 in patients with progressionfree survival (PFS) > 6 months was not significantly different from the ktrans value in patients with PFS ≤6 months (p = 0.113). The ktrans value at T0 was not significantly different between patients who were previously submitted to chemoembolization and those who were not submitted (p = 0.587). Conclusion: In this pilot study, the ktrans value may serve as a biomarker of tumor response to antiangiogenic therapy, but only 6 months after its initiation. Clinical outcomes such as PFS were not predicted before the initiation of treatment.
publisher Sociedade Portuguesa de Gastrenterologia
publishDate 2019
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452019000400006
work_keys_str_mv AT camposmarta perfusionmagneticresonanceasabiomarkerforsorafenibtreatedadvancedhepatocellularcarcinomaapilotstudy
AT candelariaisabel perfusionmagneticresonanceasabiomarkerforsorafenibtreatedadvancedhepatocellularcarcinomaapilotstudy
AT papanikolaounickolas perfusionmagneticresonanceasabiomarkerforsorafenibtreatedadvancedhepatocellularcarcinomaapilotstudy
AT simaoadelia perfusionmagneticresonanceasabiomarkerforsorafenibtreatedadvancedhepatocellularcarcinomaapilotstudy
AT ferreiracarlos perfusionmagneticresonanceasabiomarkerforsorafenibtreatedadvancedhepatocellularcarcinomaapilotstudy
AT manikisgeorgiosc perfusionmagneticresonanceasabiomarkerforsorafenibtreatedadvancedhepatocellularcarcinomaapilotstudy
AT caseiroalvesfilipe perfusionmagneticresonanceasabiomarkerforsorafenibtreatedadvancedhepatocellularcarcinomaapilotstudy
_version_ 1756004323708370944